As the ligand of EGFR, EREG is commonly upregulated in cancer types, such as non-small cell lung cancer, breast cancer, gastric cancer, head and neck cancer, ovarian cancer, colorectal cancer, brain cancer, and bladder cancer (20). This evidence concerns the gene EGFR and breast carcinoma.